Evidence map›Paper›PMID 32617447›Full record

ArticleAIMS microbiology2020

Study of therapeutic effect of different concentrations of imatinib on Balb/c model of cutaneous leishmaniasis.

Mohsen Moslehi, Fatemeh Namdar, Mahsa Esmaeilifallah, Fariba Iraji, Bahareh Vakili, Fatemeh Sokhanvari, Seyed-Mohsen Hosseini, Faham Khamesipour, Zahra Sebghatollahi, Sayed-Hossein Hejazi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIMS microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Genetic diversity ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mohsen MoslehiSkin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Fatemeh NamdarDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan.
Mahsa EsmaeilifallahDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan.
Fariba IrajiDepartment of Dermatology, Isfahan University of Medical Sciences, Isfahan, Iran.
Bahareh VakiliDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan.
Fatemeh SokhanvariSkin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Seyed-Mohsen HosseiniDepartment of Biostatistics & Epidemiology, School of Health, Isfahan University of Medical Sciences, Isfahan, Iran.
Faham KhamesipourSabzevar University of Medical Sciences, Sabzevar, Iran.
Zahra SebghatollahiDepartment of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan.
Sayed-Hossein HejaziSkin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan University of Medical Sciences · IRSabzevar University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis, as a tropical and subtropical disease, is endemic in more than 90 countries around the world. Today, cutaneous leishmaniasis (CL) that affects more than 1.5 million people per year lacks a definitive treatment approach. Imatinib is an anticancer drug that inhibits the abnormal function of Bcr-Abl due to its tyrosine kinase inhibitor, and that was the reason why the drug was tested for CL treatment because protein kinases are essential enzymes in the

Indexed as

Balb/ccutaneous leishmaniasisimatinibtherapeutic

Identifiers

PMID32617447
PMCPMC7326727
OpenAlexW3033827797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.